Sign inJoin waitlistJoin the waitlist

Saum Ghodoussipour

Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute · Rutgers Health

Credentials: · · · · ·

History

Bladder and Urothelial Cancer Program · Rutgers Health
Present
Rutgers Health
Present

Kenneth Norris Jr Cancer Hospital and Research Institute
2019–2020
University of Southern California
2014–2019
Temple University School of Medicine
2009–2013
Boston University
2005–2009

Research

A deep-learning model using automated performance metrics and clinical features to predict urinary continence recovery after robot-assisted radical prostatectomy
BJU international · 2019 · 125 citations
Experts vs super-experts: differences in automated performance metrics and clinical outcomes for robot-assisted radical prostatectomy
BJU international · 2019 · 63 citations
Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease
PLoS ONE · 2019 · 45 citations

Thomas Jang
37 papers
Hooman Djaladat
30 papers · 26 as a resident
Vignesh Packiam
30 papers
Sia Daneshmand
24 papers
Eric Singer
23 papers
AS
Arnav Srivastava
22 papers · 10 as a fellow
BL
Benjamin Lichtbroun
18 papers · 18 as a resident
David Golombos
18 papers
Hiren Patel
18 papers · 9 as a fellow
KC
Kevin Chua
18 papers · 17 as a resident
Anne Schuckman
17 papers
MF
Melinda Fu
17 papers · 17 as a resident

Clinical trials

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)
Principal investigator · Recruiting · Phase 2
Rutgers, The State University of New Jersey
2026–2029
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Principal investigator · Active not recruiting · Phase 2
Rutgers, The State University of New Jersey
2017–2027
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Site PI · Recruiting · Phase 3
UroGen Pharma Ltd.
2025–2028
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Site PI · Recruiting · Phase 2
John Sfakianos
2025–2032